MFDS Expands Regulation of Silicone Sealants with ISO 10993-12 Testing

On May 9, 2026, the Korean Ministry of Food and Drug Safety (MFDS) issued Notice No. 2026-22, bringing silicone sealants used in medical facilities, cleanrooms, and food processing environments under medical device–grade regulatory oversight. This change mandates ISO 10993-12 extractable cytotoxicity testing for affected products — a development directly relevant to manufacturers, exporters, and distributors of construction and industrial sealants serving the Korean market.

Event Overview

On May 9, 2026, the Korean Ministry of Food and Drug Safety (MFDS) published Notice No. 2026-22. The notice extends regulatory control over silicone sealants applied in healthcare infrastructure (e.g., hospitals), controlled-environment facilities (e.g., cleanrooms), and food production sites. Under this notice, such sealants are now classified as subject to medical device–level requirements, specifically requiring cytotoxicity test reports generated per ISO 10993-12 (Biological evaluation of medical devices — Part 12: Sample preparation and reference materials). Testing must be conducted at MFDS-designated laboratories, including those accredited by KOLAS (Korea Laboratory Accreditation Scheme).

Industries Affected

Direct Exporters and Trading Companies

Exporters supplying silicone sealants from China (and other non-Korean jurisdictions) into South Korea for use in regulated environments will face new conformity barriers. Compliance is no longer based solely on technical specifications or chemical composition but now requires documented biological safety evidence aligned with medical device standards.

Manufacturers and Formulators

Producers of silicone sealants intended for architectural, pharmaceutical, or food-grade applications must reassess product formulations and manufacturing controls. Even if a product was previously exempt from biocompatibility testing, its intended end-use in MFDS-defined settings now triggers mandatory ISO 10993-12 evaluation — particularly regarding leachable substances under standardized extraction conditions.

Supply Chain and Certification Service Providers

Third-party testing labs, regulatory consultants, and certification bodies supporting exporters must verify whether their current service scope includes MFDS-recognized ISO 10993-12 extractable cytotoxicity testing. KOLAS-accredited capability is now a prerequisite for valid submission support — not merely a competitive advantage.

Key Considerations and Recommended Actions

Monitor official MFDS guidance and implementation timelines

Notice No. 2026-22 specifies the regulatory trigger but does not yet clarify enforcement start dates, transitional provisions, or exemptions for existing stock or pending shipments. Stakeholders should track subsequent MFDS announcements — especially any supplementary notices or Q&A documents — before adjusting compliance strategies.

Identify and segregate affected product lines by application context

Not all silicone sealants fall under the new requirement. Only those marketed or deployed in medical buildings, cleanrooms, or food processing facilities are in scope. Companies should audit product labeling, technical datasheets, sales documentation, and distribution channels to determine which SKUs require retesting — avoiding unnecessary cost or delay for non-regulated applications.

Distinguish between policy signal and operational readiness

The notice reflects an evolving regulatory alignment with medical device safety principles, rather than an immediate import ban. However, customs clearance or post-market inspections may begin referencing this requirement once implementation takes effect. Preemptive engagement with KOLAS-accredited labs is advisable — but full-scale requalification should await confirmed deadlines.

Prepare documentation and laboratory coordination in advance

ISO 10993-12 testing involves specific sample preparation protocols, extraction media selection, and cell-line validation. Lead times for testing and reporting can extend beyond standard chemical analysis. Exporters should initiate contact with designated labs now to confirm capacity, required sample quantities, and report formatting expectations — especially for multi-component or cured-sealant samples.

Editorial Perspective / Industry Observation

Observably, this notice signals a broader trend of functional convergence: materials used in high-integrity built environments are increasingly held to biological safety standards traditionally reserved for implantables or direct-contact devices. Analysis shows that MFDS is applying risk-based logic — focusing not on material category alone, but on exposure context (e.g., proximity to sterile zones, potential for leaching into food contact surfaces). It is currently more accurate to interpret this as a regulatory signal than an immediate compliance deadline; however, its inclusion in formal notice format indicates strong institutional intent. From an industry perspective, this shift underscores the need for cross-functional alignment between R&D, regulatory affairs, and commercial teams — especially where product positioning spans general construction and mission-critical infrastructure segments.

South Korea’s move follows similar tightening in EU and U.S. frameworks around extractables and leachables in sensitive applications — though MFDS has chosen a targeted, application-driven approach rather than broad material classification. Continued monitoring is warranted, particularly for potential expansion to other sealant chemistries (e.g., polyurethane or polysulfide) or adjacent building materials.

Conclusion: This regulatory update marks a definable escalation in safety expectations for silicone sealants deployed in health- and hygiene-sensitive infrastructure. It does not represent a blanket restriction, but rather a context-specific compliance obligation tied to documented end-use. Current understanding favors interpreting it as a forward-looking regulatory alignment — one requiring careful scoping, early lab coordination, and close attention to official implementation details before operational changes are enacted.

Information Source: Korean Ministry of Food and Drug Safety (MFDS), Notice No. 2026-22, issued May 9, 2026. Pending clarification on enforcement timing and transitional arrangements remains under observation.